- Bristol Myers Squibb posted a modest gain after a double beat on earnings.
- The company continues to display strong fundamentals and a robust pipeline.
- Although growth investors may not be pleased, Bristol Myers Squibb stock remains a strong value stock.
Bristol-Myers Squibb Company (NYSE:BMY) posted a small gain after an earnings report; the company beat its top and bottom lines. The pharmaceutical company delivered earnings per share (EPS) of $1.99 on revenue of $11.22 billion. That was better than the analyst forecast for $1.83 EPS on revenue of $11.18 billion.
The results were lower when compared to the same quarter in the prior year, but both were narrow losses. Earnings per share (EPS) was off by a penny, and revenue was down 3%.
Growth investors may feel disappointed with the company’s results. However, Bristol Myers Squibb has still posted strong results that establish it as an attractive value stock, even if it may not be as undervalued as it once appeared.
BMY Stock Remains a Strong Fundamental Choice
Bristol Myers Squibb has a profit margin of over 14%, which is better than 86% of the companies in its sector. Additionally, the company’s return on assets is 6.59%, better than 91% of the industry.
The company continues to post a double-digit free cash flow (FCF) yield. Some of that FCF goes toward its dividend, which the company has increased in each of the last 12 years. These numbers take on added significance when considering that the company expects to post single-digit growth in revenue and earnings over the next five years.
The Pipeline Keeps Flowing
In the last year, Bristol Myers Squibb has launched three new drugs. Each should deliver over $4 billion in non-risk adjusted sales by 2029. The company expects to receive four more approvals by the end of 2023. The company also has a robust pipeline that includes at least 50 candidates.
What's the significance for investors?
Companies such as Bristol-Myers Squibb only enjoy patent protection for a limited time, displayed in this earnings report. The company said that Revlimid's blockbuster cancer drug sales were impacted by generic competition. Revlimid was one of three drugs, including Eliquis and Opdivo, that combine for approximately 66% of the company’s quarterly revenue. Opdivo just received encouraging results in a clinical trial that could expand its use in treating melanoma at earlier stages.
The company did reaffirm its guidance for annual sales for Revlimid, for sales between $9 and $9.5 billion. Chief financial officer David Elkins told Reuters he expects the actual number to come in at the upper end of that range.
A Safe Port for Volatile Times
BMY stock has gone up 23% in the last five years. However, the bulk of that gain has come in 2022. This is probably due to investors fleeing to safety. In that regard, Bristol-Myers Squibb delivers consistent, profitable revenue. Plus, the company delivers a dividend that pays out $2.12 annually and yields just under 3%.
BMY stock recently has bounced above its 10-, 20- and 50-day moving averages. However, the recent market rally has started to stir animal spirits in the market. If that’s the case, then growth investors may start to look at risk-on assets. That may create an opportunity for value investors who should look at every dip as an opportunity to buy shares of this still-undervalued stock.